Literature DB >> 19875067

Radiofrequency ablation of metastatic pheochromocytoma.

Aradhana M Venkatesan1, Julia Locklin, Edwin W Lai, Karen T Adams, Antonio Tito Fojo, Karel Pacak, Bradford J Wood.   

Abstract

In the present report on the preliminary safety and effectiveness of radiofrequency (RF) ablation for pheochromocytoma metastases, seven metastases were treated in six patients (mean size, 3.4 cm; range, 2.2-6 cm). alpha- and beta-adrenergic and catecholamine synthesis inhibition and intraprocedural anesthesia monitoring were used. Safety was assessed by recording ablation-related complications. Complete ablation was defined as a lack of enhancement within the ablation zone on follow-up computed tomography. No serious adverse sequelae were observed. Complete ablation was achieved in six of seven metastases (mean follow-up, 12.3 months; range, 2.5-28 months). In conclusion, RF ablation may be safely performed for metastatic pheochromocytoma given careful attention to peri-procedural management.

Entities:  

Mesh:

Year:  2009        PMID: 19875067      PMCID: PMC3608423          DOI: 10.1016/j.jvir.2009.07.031

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  22 in total

Review 1.  Phaeochromocytoma.

Authors:  Jacques W M Lenders; Graeme Eisenhofer; Massimo Mannelli; Karel Pacak
Journal:  Lancet       Date:  2005 Aug 20-26       Impact factor: 79.321

2.  Radiofrequency ablation and biopsy of metastatic pheochromocytoma: emphasizing safety issues and dangers.

Authors:  Mark D Mamlouk; Eric vanSonnenberg; Gregory Stringfellow; Dean Smith; Albert Wendt
Journal:  J Vasc Interv Radiol       Date:  2009-03-28       Impact factor: 3.464

3.  Percutaneous CT-guided radiofrequency ablation of symptomatic bilateral adrenal metastases in a single session.

Authors:  Wai-Kit Lo; Eric vansonnenberg; Sridhar Shankar; Paul R Morrison; Stuart G Silverman; Kemal Tuncali; Michael Rabin
Journal:  J Vasc Interv Radiol       Date:  2006-01       Impact factor: 3.464

4.  Pheochromocytomas: can malignant potential be predicted?

Authors:  H John; W H Ziegler; D Hauri; P Jaeger
Journal:  Urology       Date:  1999-04       Impact factor: 2.649

5.  Hypertensive crisis in a patient undergoing percutaneous radiofrequency ablation of an adrenal mass under general anesthesia.

Authors:  Eduardo N Chini; Michael J Brown; Michael A Farrell; J William Charboneau
Journal:  Anesth Analg       Date:  2004-12       Impact factor: 5.108

6.  Metyrosine and pheochromocytoma.

Authors:  J Steinsapir; A A Carr; L M Prisant; E D Bransome
Journal:  Arch Intern Med       Date:  1997-04-28

Review 7.  Pheochromocytoma: presentation, diagnosis and treatment.

Authors:  Nicole Reisch; Mariola Peczkowska; Andrzej Januszewicz; Hartmut P H Neumann
Journal:  J Hypertens       Date:  2006-12       Impact factor: 4.844

Review 8.  Clinical review: Current treatment of malignant pheochromocytoma.

Authors:  Tim Scholz; Graeme Eisenhofer; Karel Pacak; Henning Dralle; Hendrik Lehnert
Journal:  J Clin Endocrinol Metab       Date:  2007-02-06       Impact factor: 5.958

Review 9.  Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.

Authors:  Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

10.  Percutaneous radiofrequency coagulation of osteoid osteoma compared with operative treatment.

Authors:  D I Rosenthal; F J Hornicek; M W Wolfe; L C Jennings; M C Gebhardt; H J Mankin
Journal:  J Bone Joint Surg Am       Date:  1998-06       Impact factor: 5.284

View more
  9 in total

Review 1.  Percutaneous ablation of adrenal tumors.

Authors:  Aradhana M Venkatesan; Julia Locklin; Damian E Dupuy; Bradford J Wood
Journal:  Tech Vasc Interv Radiol       Date:  2010-06

Review 2.  Interventional radiology of the adrenal glands: current status.

Authors:  Anna Maria Ierardi; Mario Petrillo; Francesca Patella; Pierpaolo Biondetti; Enrico Maria Fumarola; Salvatore Alessio Angileri; Filippo Pesapane; Antonio Pinto; Gianlorenzo Dionigi; Gianpaolo Carrafiello
Journal:  Gland Surg       Date:  2018-04

Review 3.  Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.

Authors:  Victoria L Martucci; Karel Pacak
Journal:  Curr Probl Cancer       Date:  2014-01-15       Impact factor: 3.187

Review 4.  Image-guided adrenal and renal biopsy.

Authors:  Karun V Sharma; Aradhana M Venkatesan; Daniel Swerdlow; Daniel DaSilva; Avi Beck; Nidhi Jain; Bradford J Wood
Journal:  Tech Vasc Interv Radiol       Date:  2010-06

Review 5.  Image-guided ablation of adrenal lesions.

Authors:  Koichiro Yamakado
Journal:  Semin Intervent Radiol       Date:  2014-06       Impact factor: 1.513

Review 6.  Metastatic paraganglioma.

Authors:  Stephanie M J Fliedner; Hendrik Lehnert; Karel Pacak
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

7.  Comparison of the radiofrequency ablation versus laparoscopic adrenalectomy for aldosterone-producing adenoma: a meta-analysis of perioperative outcomes and safety.

Authors:  Run-Qi Guo; Yuan-Ming Li; Xiao-Guang Li
Journal:  Updates Surg       Date:  2021-06-24

8.  Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma.

Authors:  Jacob Kohlenberg; Brian Welch; Oksana Hamidi; Matthew Callstrom; Jonathan Morris; Juraj Sprung; Irina Bancos; William Young
Journal:  Cancers (Basel)       Date:  2019-02-07       Impact factor: 6.639

9.  Clinical Outcomes following Percutaneous Radiofrequency Ablation of Unilateral Aldosterone-Producing Adenoma: Comparison with Adrenalectomy.

Authors:  Ammar Sarwar; Olga R Brook; Anand Vaidya; Ari C Sacks; Barry A Sacks; S Nahum Goldberg; Muneeb Ahmed; Salomao Faintuch
Journal:  J Vasc Interv Radiol       Date:  2016-05-27       Impact factor: 3.464

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.